Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 28 of 28.
Jul 2007
3 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 03, 2007, titled "Glenmark receives tentative US FDA approval for Terbinafine Hydrochloride tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 02, 2007, titled "Glenmark receives tentative US FDA approval for its ANDA for Topiramate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
29 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 29, 2007, titled "Glenmark receives US FDA approval for Ondansetron IR and Ondansetron ODT tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jun · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the Postal Ballot pursuant to Section 192A of the Companies act, 1956 read with the Companies (Passing of Resolution by Postal ballot ) Rules, 2001 to transact the Special Business by the Members by passing Resolution through Postal Ballot. The Company has appointed Mr. Surjan Singh Rauthan, Practising Company Secretary, Mumbai, as the Scrutinizer for conducting the Postal Ballot in a fair and transparent manner. The duly completed Postal Ballot Form in the enclosed self addressed pre-paid postage envelope reaches the Scrutinizer on or before the close of working hours on July 24, 2007. The Scrutinizer shall submit his report to the Chairman of the Company after completion of the scrutiny and the results of the Postal Ballot shall be announced on July 27, 2007 at the Corporate office of the Company. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jun · Allotment of shares/ others
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Compensation Committee of the company, at its meeting held on 22nd June, 2007 has cancelled 89,250 (Adjusted after split of face value from Rs.10/- to Rs.2/- and issue of bonus equity shares in the ratio 1:1) stock options issued pursuant to ESOP 2003, owing to employees leaving the services of the company". The Company has further informed that "The Compensation Committee of the Board of Directors at their meeting held today i.e. 22nd June, 2007 alloted 5,550 shares to the employees of the company on exercise of options granted to them pursuant to ESOP 2003".21 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 21, 2007, titled "Glenmark receives tentative US FDA approval for its ANDA for Terbinafine HCL tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Jun · Corporate action
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company at their meeting held today (i.e. June 11, 2007) have approved the sub-division of the equity shares of the Company from Rs.2/- per share to Re.1/- per share, subject to the approval of the shareholders by way of Postal Ballot".8 Jun · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange on June 08, 2007 that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 4,000,000 into 3,44,988 Equity Shares at a price of Rs.506.22 per share of face value of Rs.2/- each out of US$ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".5 Jun · Issue of Equity shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "At the meeting of Operations Committee of the Board of Directors held today (June 05, 2007), the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 1,000,000 into 1,01,253 Equity Shares at a price of Rs.431.197 per share of face value Rs.2/- each out of US$ 20,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".4 Jun · News Verification
News Verification : The media had reports on June 02, 2007 that Glenmark Pharmaceuticals Ltd. may announce a bonus issue. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Glenmark Pharmaceuticals Ltd. has vide its letter inter-alia stated, "We would like to clarify that the company has not decided regarding bonus issue and confirm that the company has not given any information regarding announcement of bonus issue to the media/ any other person and therefore we have no comments on the source of the news item."4 Jun · Board meeting
To consider the split of Equity Shares of the Company.
May 2007
28 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "Glenmark Pharmaceuticals S.A. (GPSA), the Swiss subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), has entered Phase II clinical trials for GRC 6211 in Europe". A copy of the press release dated May 28, 2007, titled "Glenmark's lead candidate for pain, GRC 6211, to enter Phase II trials in Europe" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 16, 2007, titled "Glenmark receives US FDA approval to market generic Pravastatin Sodium, Naproxen Sodium and Naproxen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 May · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "At the meeting of Operations Committee of the Board of Directors held today (May 10, 2007), the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 500,000 into 43,123 Equity shares at a price of Rs.506.22 per share of face value Rs.2/- each out of US$ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".3 May · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "At the meeting of Operations Committee of the Board of Directors held today (April 30, 2007), the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 2,500,000 into 253,132 Equity shares at a price of Rs.431.197 per share of face value Rs.2/- each out of US$ 20,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".
Apr 2007
25 Apr · Miscellaneous
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of presentation made at the analyst meet. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Apr · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the presentation made at the analyst meet titled "Management Discussion and Analysis for Fourth Quarter and Financial Year 2006-07 ended 31st March, 2007". Further, the company has also informed the Exchange regarding a press release dated April 25, 2007, titled "Glenmark posts 64% consolidated revenue growth with an increase of 254% in consolidated net profit for FY07". The details of the both shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Apr · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "At the meeting of Operations Committee of the Board of Directors held today (April 20, 2007), the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 2,000,000 into 202,506 Equity shares at a price of Rs.431.197 per share of face value Rs.2/- each out of US$ 20,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".16 Apr · Board meeting
To consider and approve the Audited Financial Results for the 4th Quarter / Year ended March 31, 2007.
Mar 2007
29 Mar · Issue of Stock Options
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "the Compensation Committee of the Company, at its meeting held on 21st March, 2007 has issued 1,80,500 stock options to the employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Rs.2/- each in one or more tranches".28 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 28, 2007, titled "Glenmark Confirms ANDA Filing with a Paragraph IV Certification for Zetia (R) Tablets". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release towards conclusion of deal by Glenmark Holding SA, Switzerland a wholly owned subsidiary of the Company, to acquire a majority shareholding (>90%) of Medicamenta a.s, a pharmaceutical marketing and manufacturing Company in the Czech Republic. The copy of the press release dated March 26, 2007, titled "Glenmark concludes deal to acquire Medicamenta a.s., a pharmaceutical marketing and manufacturing company in the Czech Republic" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Mar · E-mail ID for Investor Complaints
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the company has designated an e-mail ID for purpose of registering the complaints of investors: complianceofficer@glenmarkpharma.com.12 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 12, 2007, titled "Dyax Corp. and Glenmark Enter Into Funded Research Agreement for Discovery of Therapeutic Antibodies". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2007
28 Feb · Miscellaneous
Glenmark Pharmaceuticals Ltd. has informed the Exchange that The compensation Committee of the company, at its meeting held on 28th February, 2007 has cancelled 84,700 (Adjusted after split of face value from Rs.10/- to Rs.2/- and issue of bonus equity shares in the ratio 1:1) stock options issued pursuant to ESOP 2003, owing to employees leaving the services of the company. We would further like to inform you that the Compensation Committee of the Board of Directors at their meeting held today i.e. 28th February, 2007 alloted 8,500 shares to the employees of the company on exercise of options granted to them pursuant to ESOP 2003.13 Feb · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange on February 12,2007 that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 1,500,000 into 151,879 Equity Shares at a price of Rs.431.197 per share of face value of Rs.2/- each out of US$ 20,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".1 Feb · Miscellaneous
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of presentation made at the analyst meet. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
29 Jan · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 1,500,000 into 151,879 Equity Shares at a price of Rs.431.197 per share of face value of Rs.2/- each out of US$ 20,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".23 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release, dated January 23, 2007, titled "Glenmark posts for Q3 FY07 consolidated revenue growth of 118% and consolidated profits of Rs. 1889.2 million." The details of the press release and Management Discussion & Analysis shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jan · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange on January 23,2007 that: "At the meeting of Board of Directors held today the Board has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 500,000 into 50,626 Equity Shares at a price of Rs.431.197 per share of face value of Rs.2/- each out of US$ 200,00,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".16 Jan · Board meeting
Meeting on 23 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”